Imugene Ltd (PK) (IUGNF) Quote

Great news,

https://hotcopper.com.au/threads/ann-final-her-vaxx-phase-2-trial-overall-survival-results.6811978/?source=email

Gary

Very good news - https://finance.yahoo.com/news/city-hope-imugene-announce-first-230000055.html

1st patient dosed

Not so good news - The trial is anticipated to run for approximately 24 months - or it will end in 2025

Imugene granted patent in Japan!

https://www.imugene.com/announcements

Thanks, it doesn't seem to want to accept my Zip code as Postal Code, I couldn't sign up for the ap. I will try it in the web browser.

Right now my biggest investment is NWBO, I suggest it to anyone to take a look, I believe big news on it's Phase 3 Trial should be out in the next 2 months, or less. In glioblastoma roughly 1/3rd the patients in the trial have lived for over 5 years, normally less than 5% last that long. I believe it could be huge.

Gary

Hi Skitahoe, there is a fountain of knowledge on the website and app called “hot copper” . All ASX stocks are discussed. Search for $IMU

Some good news and updates

https://app.sharelinktechnologies.com/announcement/asx/134637c30ee3b1888c8ed9ecc53eb042

Is long update from the company - good to read about the company before making investment decision

https://app.sharelinktechnologies.com/announcement/asx/73ab09ccbc31c8cac80dace31ceb38df

Thanks, definitely gives me some food for thought. My biggest incentive was seeing that City of Hope had licensed a product they developed to them, as a patient there I greatly respect what they're doing there.

I'll probably keep it on my radar, but may not take a position, at least for awhile. Are there any sites where more can be found about the company. I agree with you that billions of shares outstanding isn't great, but it seems like companies are treating billions of shares the way they used to treat millions.

Gary

Here is my reading/views - not an opinion for others to invest

Company has some interesting technology - they are innovators - getting into collaborations.

The path to actual success is very long - also the co has $ 1 B market cap it is fully or overvalued. For me if the market cap was in $300-400 m them there was some opportunity to make money.

In oncology space there are too many promising clinical stage co - so picking a winner is difficult - I am not sure if I should invest. I have considered and added starting position but it is like a gamble

My attention was called to this company when I read about the company licensing a product from City of Hope. I'm a patient at City of Hope, in remission for over 6 years since receiving stem cells for leukemia. I believe my Dr. may have participated in the genesis of the drug.

I'm considering an investment and would like to know where I can learn more about the company. I'd like to hear the opinion of other investors.

Gary

Anyone here? Seems vo has made a lot of progress in last few months
Also SP has gone up from 10 cents to 34 cents

"I believe you are about to see the faith you've placed in us be acknowledged in a positive fashion," Paul Hopper, Chairman.

See attached link to December newsletter

chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5fc72d1f3ac9c763f4d28c70/1606888739244/IMU4260_Newsletter_OctHol+2020_Web.pdf

Updated Bell Potter price target

chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5fc82f15f97c193540e5fed1/1606954779040/IMU20201203.pdf

GREAT NEWS! Wow, this is amazing. Can't believe there isn't more action here.

https://www.imugene.com/announcements


IMUGENE LIMITEDACN 009 179 551WWW.IMUGENE.COMinfo@imugene.comASX Announcement Imugene’s HER-Vaxx shows positive Overall Survival with Hazard Ratio of 0.418in Ongoing Randomized Phase 2 Trial in AdvancedGastric Cancer.

•Interim analysis in the randomized Phase 2 showed statisticallysignificant overall survival Hazard Ratio (HR) of 0.418 (80% 2-sided CI: 0.186, 0.942); HER-Vaxx showed a reduced risk of death of 58.2% in the HER-Vaxxplus chemotherapy group as compared to chemotherapy alone.•Themedianoverall survival (OS) for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8months in patients treated with chemotherapy alone.•The Phase 2 data represent a clinical proof-of-concept signal for HER-Vaxx when added to chemotherapy and indicate that B-cell activating immunotherapyvaccines can induce clinically active antibody responses.•The Independent Data Monitoring Committee (IDMC) confirms a favourable survival outcomewith no added toxicityforHER-Vaxx combinedwith SOC chemotherapyover chemotherapy alone and advises to lower the number of patients required for study completion. Sydney, Australia, 23November2020:Imugene Limited(ASX:IMU),a clinical stage immuno-oncology company,is pleased to share positive interim data from its ongoing Phase 2 study of HER-Vaxx in Her-2/Neu overexpressing advanced/metastatic gastric/GEJcancer.HER-Vaxx Phase 2 interim analysis safety and efficacy data were reviewed at the IDMCmeeting.As a result of the review, theIDMC reported no safety concernsand viewed this preliminary data as strongly in favour of a HER-Vaxxsurvival effect. The interim analysis results from this clinical proof-of-concept study,which was designed with a specified 1-sided false positive probability of 0.10,showedtwice as many patients survived on the HER-Vaxx plus SOC chemotherapy treatment arm compared totheSOC chemotherapy control arm. This translated into an overall survival HR of 0.418 (80% 2-sidedCI: 0.186, 0.942) witha statistically significant 1-sided p-value of 0.083. There was no difference in safety eventsbetween the two treatment arms, suggesting that HER-Vaxx does not add toxicity to SOC chemotherapy. The longestHER-Vaxx treated patient remains on therapy and progression-free 16.3 months after dosing. Historical
2IMUGENE LIMITED ACN 009 179 551 data fromthe ToGA Phase 3 study which examined the effect of Herceptin plus chemotherapy versus chemotherapy alone in advancedgastric cancer, had an overall survival HR of 0.74for the intent-to-treat analysis. The study included thesame patient population of HER2 overexpressing patients in the HER-Vaxx Phase 2 study. The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the studygiven the strong signal observed in the data. Imugene’s MD & CEO, Mrs Leslie Chong said, “I am delightedto report that we have achieved this significant milestonefor patients with advanced gastric cancer. I am excited that the interim analysis favoured the survival outcome for HER-Vaxx and the IDMC suggested to shorten the study by lowering the number of patients. This data represents a clinical proof-of-concept for HER-Vaxx and supports our B-cell activating immunotherapy platform. I look forward to updating the market as the data matures.” Imugene’s HER-Vaxxis a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies, in Phase Iand now Phase 2 studiesto stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein. The study is randomised into two arms of either HER-Vaxx plus standard-of-care chemotherapy or standard-of-care chemotherapyalone. The primary endpoint is overall survival and secondary endpoint will be progression-free survival. Safety, tolerability and immune response will also be measured.The Phase 2 trial is being conducted at multiple sites across Eastern Europe and India where clinicians have difficulty accessing approved antibody treatments such as Herceptinâand Perjetaâmarketed by Swiss multinational Roche Holding AG. There is also a high prevalence of gastric cancer in the countries selected. Full study details can also be found on clinicaltrials.gov under study ID: NCT02795988

Dead site. Hotcopper is where it's at.

Up 10 percent aussie side tonight woo!! High volume again!! I added 3 times last week...let's gooo

This is awesome. I only have 21k shares in this, but it's one of the first stocks I've bought. I'm +$345 and it feels good, I hope it goes over $1.

Anyone here,, this is getting JUICY!!! STARTING TO HAVE HUGE VOLUME ON ASX AND PRICE COMING UP GOOD LETS GOOOO

Roth Capital just initiated coverage as a buy at .13.

https://t.co/FaKmt7Kqyh?amp=1

This stock is starting to get rolling!! NR one after the other! 30 mill in bank, met with US FDA to discuss matters, and CEO exercised and held on to shares...this is look nice!

Lots of clues in this interview yesterday with Leslie Chong of Imugene.

Volume up today at almost 600K and the ASX has been huge for several days. General consensus is big news pending and Laurence Fishburn documentary to be launched about Imugene on Monday.

I believe but have no hard knowledge that price sensitive news will possibly be released to coincide with the documentary and it's been due for sometime on Her-Vaxx phase 2 clinical trials.

Videos, news letters etc from Imugene indicate some good potential releases. Good luck to all who invest in Imugene. Most importantly, a great new way to treat cancer afflicted.

Imugene is up another 20% on the ASX last night. The ads are on US TV now on MSNBC, CNN, Discovery and others. The Laurence Fishburn documentary on Imugene airs Monday and several time throughout the next 12 months on I think PBS.

I expect more very positive announcements over the next coming weeks. I believe the time has come we will see more positive news on Her-Vaxx and others.

Also, with positive results will come the interest of big pharma if not already there and some potential licensing deals and maybe buyout. All in my opinion but seems poised in this direction based in recents news, videos by LC and other info.

Up 21.48% today on great news coming out. Documentary on prime time with Laurence Fishburn, new trials beginning, seemingly great data on phase 2 of Her-Vaxx pending and more.

https://twitter.com/TeamImugene/status/1284978851303522313?s=19

https://twitter.com/TeamImugene/status/1284978851303522313?s=19

Imugene commercials now on prime time leading up to Lawrence Fishburn documentary on the company.

Watch it soar investors. Better get in board while you can.

https://twitter.com/TeamImugene/status/1284978851303522313?s=19

Announcements are rolling out. Now PD-1 Vaxx is starting phase 1. IUGNF is exciting.

Very exciting things Imugene is doing. I expect some news out soon on phase 2 of HerVaxx. Hope all is as good as I think it will be.

Thank you kindly! I did read the hotcopper report and feel very confident now after finding imugene doing my own reserach in up and coming biotechs. I appreciate the posts and will follow you. thank you.

Yes, I hold a significant amount. Phase 2 HerVaxx data due anytime. I am unsure of USA listing and suspect big pharma will swoop in and buy them up before that if it was planned. USA listing would definitely bring much more on share price.

Reverse split would be cool in my book. They have a lot of IP and a great board. Imugene will go high with positive HerVaxx news and new clinical trials for CF33 etc.

Go to hotcopper.com under imugene and read there. A lot of good info and some bad too.

Are there any other folks out there watching IUGNF in anticipation? I hold around 100K shares at .0275 cost per share. I really think that there is opportunity here, but somewhat expect some type of reverse split and eventual NASDAQ listings. Am I correct in my thoughts here? I would assume this would be natural as they try and attract a buyer as their clinicals progress. I really believe that they have some type of large announcement coming soon as there has not been any announcements/releases since May 28th, when looking back through their announcements they are typically very vocal every 7-10 days. Also when looking at their website I can notice almost daily improvements to the look and feel of the site. I do believe we are in for a nice increase, however the ASK/BID spread worries me a bit but assume it may be natural in these lower cap OTC stocks. Any feedback from another interested IUGNF watcher would be welcome. I expect to hold throughout the next 12-18 months as their projected cash reserves have them at 24 months+.

That post was good. I read Hot Copper daily. Right now huge volume on ASX and price keeps creeping up.

I hold a significant amount of IUGNF and believe it will continue up. With new clinical trials starting and HerVaxx phase 2 data out soon I believe we will see very strong share price increases.

Interesting point on IMU hotcopper (go to hotcopper for further review:)

https://hotcopper.com.au/threads/why-imu-is-a-multi-multi-bagger.5431324/

I have mentioned in previous posts i don’t believe the ASX market has attributed any value whatsoever to CF33 at current prices, or even at 10-12c for that matter.
We have a super impressive pipeline . “Game changing, paradigm shift, potentially disruptive to market leading blockbuster monoclonal antibodies and chemotherapy” , are the things being said.
A sum of the parts valuation today by any metric simply can not reasonably equal 3.5 for what has already been demonstrated to work!

HerVax + PD1 Vax+ CF33+ Mimitopes = US$ 100million! Seriously?

With HerVax the original Imugene product already advanced to halfway through Ph2 this is what the market is primarily focusing on and attributing current value.
How about attributing some realistic value for CF33.
Just look closely at the Oncolytic Virus landscape.
As four starting points ;

It's up 15% now on ASX on news yesterday from phase 2 clinical trials. I'm in TX from AZ and in long. Their IP is good, world class leadership and it will in my opinion make a lot of investors very happy.

This company looks great

https://t.co/IXotYN9MaE?amp=1

Good info. I am accumulating at these low prices. I think good news coming on HerVaxx too.

Sorry site reposted with error.

I hold a nice piece as I've stated before and am seeing some good legit stuff coming out. Phase 2 on Her-Vaxx due any time. Lots in the pipeline and big pharma have been making aquisitions so article below is good.

It's cheap now but I suspect in next 3 months it will be much more.

https://www.thepharmaletter.com/article/eligible-imugene-thinking-ahead-to-actively-developing-a-bd-department

I hold a nice piece as I've stated before and am seeing some good legit stuff coming out. Phase 2 on Her-Vaxx due any time. Lots in the pipeline and big pharma have been making aquisitions so article below is good.

It's cheap now but I suspect in next 3 months it will be much more.

https://www.thepharmaletter.com/article/eligible-imugene-thinking-ahead-to-actively-developing-a-bd-department

Been away for a while moving. I have a significant holding in IUGNF and today they just got US patent for Her-Vaxx. I think interim phase 2 is looming and patent protects it. I suspect they may be large Pharma buyers looking.


It's up over 13% on ASX TONIGHT SO I think tomorrow in USA should be good movement up. I believe in them and feel it will pay off soon.

Quite a few outstanding shares. Seems like an R/S is a foregone conclusion at some point ... unless they just don’t care since they’re on the AUX. Could they uplist to NASDAQ if they get over $1 a share on their own? Likelihood of that happening?

CF33 Oncolytic Virus GMP Manufacturing Update

SYDNEY Australia 25 November 2019: Imugene Limited (ASX: IMU) is pleased to provide a GMP
manufacturing update for its CF33 oncolytic virus technology, which is due to enter clinical trials in
2020.
The CF33 oncolytic virus (OV) was developed in the lab of Professor Yuman Fong, an internationally
recognised surgeon and scientist at City of Hope, a world-renowned independent research and
treatment centre for cancer, diabetes and other life-threatening diseases based in California.
As previously announced, CF33 has been developed in two different constructs: one version of the
OV is “armed” with an immune checkpoint inhibitor inserted in the virus, which is known as
CheckVacc; and the other an unarmed construct, known as Vaxinia. It is planned by Imugene that
two separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a
Vaxinia construct of the OV.
Both constructs have completed clinical grade GMP batches at the City of Hope Center for
Biomedicine and Genetics (CBG).
The CBG is a California-licensed, 20,000 square foot, multi-product biologics manufacturing facility
within City of Hope. With twelve ISO 7 production rooms in three product type “zones”, a dedicated
aseptic fill suite and a staff with extensive biopharmaceutical experience, the CBG is capable of
producing virtually any type of biologic at scales suitable for Phase I through Phase II clinical
trials.
Imugene’s M.D. & CEO, Ms Leslie Chong said, “This is a significant milestone met in our
preparation for commencing our planned CF33 oncolytic virus Phase 1 clinical trials in 2020”.
For further information please contact:
Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

$IUGNF: If MERCK is involved with IMUGENE

Don't worry........ I'm building a nice position.


It won't catch scanners just yet, but this dev't drug that has
moved along will very soon.


The Enterprise value is Beyond compelling at this current Shareprice.

You'd be an idiot to pass it buy.


Gonna keep acquiring here.


Have a good ONE !



GO $IUGNF

I have a feeling this stock hits scanners today Good to see you EZ.

You can see how little success I made this morning at trying to fill the Intro Area of this board. I am not that computer savvy. I could not even get the font any larger to tell about the video

If you are good with filling out intros on message boards, would love to see you make yourself a moderator in order to do so.

Good luck with the stock

$IUGNF: WOW... I was just reading this in the Presentation-DECK

This sounds massive.

AUD$502Million ?????

I mean... is the market missing this or what.


https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5dc57c68e3c33a4d9dd9c611/1573223561238/Imugene+AGM+2019.pdf






I'm getting in with a position for sure.



$IUGNF at $0.05....... looks very cheap relative to value of Acquisition.



GO $IUGNF

Imugene Limited(ASX: IMU) ONCOLYTIC VIRUS ACQUISITION COMPLETE

Monday, 18th November 2019

Imugene’s MD and CEO, Ms Leslie Chong said “we are delighted to be able to complete the acquisition of
Vaxinia Pty Ltd and City of Hope licence of such a promising next generation oncolytic virus in a competitive
market place where big pharma companies are actively seeking OV technologies. CF33 comes with robust
intellectual property and long patent life, compelling pre-clinical efficacy and safety, and is anticipated to enter two Phase 1 clinical trials in 2020.”

$$GO IUGNF$$

no. the AS is determined. thr flost is determined. the restricted is determined. the rest is treasury

no, they dont print
yes they will issue shares like a treasury. its called dilution

MMs still have to get their shares. They do not just print them like the Federal Reserve. Shares are put onto the market for MMs to sell by those who have them (the float).

that is not true at all
they absolutely do that. yes

omg yes. once the shares are issued how do you think MMs get on a ticker?? they buy amongst each other. thats why shares retrain and ppl scream

look this is a game of chess
i cannot believe im entertaining that claim

Well, it is not like the MMs just mysteriously see a stock and say, "Hey, looks like we need to be selling some of this, let's print shares". They get their shares from those who own them to sell.

From what I can tell, looks like most shares are insider owned and the way it seems to trade maybe they are hanging on to those shares. Very low volume and the ASK goes high without much buying.

Found it with Sink or Swim scanner

Short video